Pharmacologic studies of intra-hepatic artery chemotherapy with degradable starch microspheres.
The effect of degradable starch microspheres (DSM) on the pharmacokinetics of 4 drugs administered via the hepatic artery was studied in 5 patients with colon carcinoma metastatic to the liver. The 4 drugs were 99m-technetium diethylenetriamine pentaacetic acid (99mTc-DTPA), an agent which is not metabolized in the liver, and floxuridine, doxorubicin, and mitomycin, agents which undergo hepatic metabolism to varying extents. DSM transiently decreased arterial blood flow to normal liver an average of 64% and to hepatic tumor an average of 78%. DSM increased tumor exposure to DTPA by a mean of 1.71-fold, and increased hepatic exposure by 1.46-fold, but did not affect total plasma exposure. In contrast, DSM did reduce total plasma exposure to floxuridine by a mean of 34%, and to mitomycin by 20%. No information was available on the effect of DSM on plasma doxorubicin levels which never exceeded the limits of detection. Variation in the injection rate of DSM did not appear to influence the relative advantages produced in tumor or plasma AUCs. The estimated increase in tumor exposure produced by DSM was 3.8-fold for floxuridine, and 3.0-fold for mitomycin. These results reflect the differences in extent of hepatic metabolism of these agents, and agree closely with predictions made from mathematical models. Although DSM improved the therapeutic index, the increase in tumor exposure was insufficient to produce significant tumor regression.
D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism*; D004317:Doxorubicin / Q000378:metabolism; D005467:Floxuridine / Q000378:metabolism; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial / Q000379:methods*; D007700:Kinetics; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D008937:Mitomycins / Q000378:metabolism; D004369:Pentetic Acid / Q000378:metabolism; D013213:Starch / Q000008:administration & dosage* / Q000009:adverse effects; D013667:Technetium / Q000378:metabolism; D016284:Technetium Tc 99m Pentetate
D000970:Antineoplastic Agents; D008937:Mitomycins; D005467:Floxuridine; D013667:Technetium; D004369:Pentetic Acid; D004317:Doxorubicin; D013213:Starch; D016284:Technetium Tc 99m Pentetate